BioNexus Gene Lab Corp (BGLC) is a Medical Specialities company listed on NASDAQ. In the last 30 days Quantisnow tracked 1 wire item for BGLC, including 1 press release or news item. The most recent was published Oct 30, 2026.
Financial highlights
Full financials- Revenue, TTM
- $3.13M
- Revenue growth
- -67.3%
- Net income, TTM
- -$2.58M
- Net margin
- -82.4%
- Free cash flow, TTM
- -$853.6K
- Cash
- $1.23M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks19-50%
2026-05-172026-11-08
Mix990d
- Insider5(56%)
- SEC Filings2(22%)
- Other2(22%)
Activity · 52 weeks3522 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRBioNexus Launches New Corporate Website with Expanded Business and Investor ResourcesKUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company") today announced the launch of its redesigned corporate website at www.bionexusgenelab.com, providing investors, business partners and other visitors with a more comprehensive view of the Company’s operations and development initiatives. The website brings together information about MRNA Scientific’s RNA screening business, Chemrex’s industrial chemical and composite-materials business, and BioNexus’ recent healthcare investments and technology relationships. Dedicated technology pages explain blood-based genomic screening and the VitaGuard™ molecular residual disea
- SECSEC Form 8-K filed by BioNexus Gene Lab Corp8-K - BioNexus Gene Lab Corp (0001737523) (Filer)
- PRRYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene LabKUALA LUMPUR, Malaysia, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Ruanyun Edai Technology Inc. (NASDAQ:RYET) ("RYET" or the "Company") today announced that it has signed a definitive agreement under which, on closing, RYET would grant BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BGLC") an exclusive license of its Cogni AI document-intelligence platform for healthcare in Malaysia, together with a reciprocal share exchange. The agreement would take Cogni AI into a new industry and a new market outside China. RYET would be entitled to a 10% royalty on qualifying technology receipts collected by BGLC and its affiliates and would receive 560,000 BGLC shares at closing, 150,000 of them in exchange for 500,00
- INSIDERChief Executive Officer Tan Lee Su-Leng was granted 338,709 shares (SEC Form 4)4 - BioNexus Gene Lab Corp (0001737523) (Issuer)
- INSIDERDirector Yap Chee Keong was granted 32,258 shares (SEC Form 4)4 - BioNexus Gene Lab Corp (0001737523) (Issuer)
- INSIDERDirector Bin Abdul Hamid Muhammad Azrul was granted 32,258 shares (SEC Form 4)4 - BioNexus Gene Lab Corp (0001737523) (Issuer)
- INSIDERChief Financial Officer Chong Set Fui was granted 96,774 shares (SEC Form 4)4 - BioNexus Gene Lab Corp (0001737523) (Issuer)
- INSIDERDirector Low Jook Yuen was granted 16,129 shares, increasing direct ownership by 1,279% to 17,390 units (SEC Form 4)4 - BioNexus Gene Lab Corp (0001737523) (Issuer)
- SECSEC Form 10-Q filed by BioNexus Gene Lab Corp10-Q - BioNexus Gene Lab Corp (0001737523) (Filer)
- INSIDERNew insider Fidelion Diagnostics Pte. Ltd. claimed ownership of 392,329 shares (SEC Form 3)3 - BioNexus Gene Lab Corp (0001737523) (Issuer)
- INSIDERNew insider Tan Lee Su-Leng claimed no ownership of stock in the company (SEC Form 3)3 - BioNexus Gene Lab Corp (0001737523) (Issuer)
- INSIDERNew insider Bin Abdul Hamid Muhammad Azrul claimed no ownership of stock in the company (SEC Form 3)3 - BioNexus Gene Lab Corp (0001737523) (Issuer)
- INSIDERNew insider Yap Chee Keong claimed no ownership of stock in the company (SEC Form 3)3 - BioNexus Gene Lab Corp (0001737523) (Issuer)
- INSIDERNew insider Low Jook Yuen claimed ownership of 1,261 shares (SEC Form 3)3 - BioNexus Gene Lab Corp (0001737523) (Issuer)
- INSIDERNew insider Chong Set Fui claimed no ownership of stock in the company (SEC Form 3)3 - BioNexus Gene Lab Corp (0001737523) (Issuer)
- SECBioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BioNexus Gene Lab Corp (0001737523) (Filer)
- PRBioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working VisitKUALA LUMPUR, Malaysia, July 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company") today announced continued progress toward commercializing the VitaGuard™ molecular residual disease ("MRD") platform in Southeast Asia following a recent working visit to facilities of the Tongshu Gene group ("Tongshu Gene") in Shanghai and Changzhou, China, led by Dr. Muthu Meyyappan, Chief Commercial Officer of Fidelion Diagnostics Pte. Ltd. ("Fidelion"). The visit combined technical planning with meetings at selected Chinese hospitals where VitaGuard is in paid commercial use. VitaGuard is a tumor‑naive, fixed‑panel liquid‑biopsy platform that uses next‑generati
- SECBioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Regulation FD Disclosure, Financial Statements and Exhibits8-K - BioNexus Gene Lab Corp (0001737523) (Filer)
- PRBioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-DevelopmentKUALA LUMPUR, Malaysia, May 29, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), a technology-focused company advancing innovation across biotechnology, precision diagnostics, and emerging healthcare platforms, today highlighted its participation in the 2026 China–Malaysia Economic Cooperation Outlook Forum, held on May 21, 2026 at the Mandarin Oriental Hotel in Kuala Lumpur. The forum, held under the theme "Advancing Biotechnology and Healthcare Collaboration towards a China–Malaysia Community with a Shared Future," brought together government representatives, industry leaders, investors, healthcare professionals, and experts from Malaysia and
- SECSEC Form 10-Q filed by BioNexus Gene Lab Corp10-Q - BioNexus Gene Lab Corp (0001737523) (Filer)
- SECSEC Form 10-K filed by BioNexus Gene Lab Corp10-K - BioNexus Gene Lab Corp (0001737523) (Filer)
- SECSEC Form NT 10-K filed by BioNexus Gene Lab CorpNT 10-K - BioNexus Gene Lab Corp (0001737523) (Filer)
- SECBioNexus Gene Lab Corp filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - BioNexus Gene Lab Corp (0001737523) (Filer)
- PRBioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD PlatformKUALA LUMPUR, Malaysia, March 11, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) today announced that, in connection with its Fidelion Diagnostics Pte. Ltd ("Fidelion") transaction, Dr. Muthu Meyyappan has been appointed Chief Commercial Officer of Fidelion. Fidelion is a precision diagnostics company focused on advancing next-generation oncology testing technologies, including minimal residual disease (MRD) liquid biopsy assays. Fidelion serves as the international intellectual property and commercialization vehicle for the VitaGuard™ MRD technology developed by Tongshu Gene, supporting commercialization initiatives outside Greater China. BGLC is a strategic investor in Fi
- SECBioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BioNexus Gene Lab Corp (0001737523) (Filer)
BGLC FAQ
8 questionsWhat is the latest news on BGLC?
In the last 30 days Quantisnow tracked 1 wire item for BGLC: 1 press release or news item. The most recent was published on October 30, 2026.What is BGLC revenue?
BioNexus Gene Lab Corp (BGLC) reported $3.13M of revenue for the twelve months ended Jun 30, 2026. That is down 67.3% from the year before. Revenue for fiscal 2025 was $7.42M.Is BGLC profitable?
No. BioNexus Gene Lab Corp reported a net loss of $2.58M for the twelve months ended Jun 30, 2026.How much cash and debt does BGLC have?
BioNexus Gene Lab Corp reported $1.23M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does BGLC stock trade?
BioNexus Gene Lab Corp (BGLC) is listed on NASDAQ.What sector and industry is BGLC in?
BioNexus Gene Lab Corp operates in the Health Care sector, Medical Specialities industry.What companies are similar to BGLC?
Notable peers in the same industry include ELV (Elevance Health Inc.), HUM (Humana Inc.), NTRA (Natera Inc.), CI (The Cigna Group), UNH (UnitedHealth Group Incorporated). Compare BGLC side-by-side with any of them on Quantisnow.How can I track BGLC on Quantisnow?
Quantisnow aggregates BioNexus Gene Lab Corp's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BGLC to receive live email and push alerts on every new disclosure.